Clinical Trial News and Research

RSS

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.

11 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

Aradigm reports $1.3M net income for third quarter 2010 vs. $3.0M net loss for third quarter 2009

Aradigm Corporation today announced financial results for the third quarter and nine months ended September 30, 2010.

11 Nov 2010

Labopharm third quarter total revenue increases to $9.6 million

Labopharm Inc. today reported its financial results for the third quarter and first nine months ended September 30, 2010.

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Exhausted neurons die prematurely and trigger disease symptoms

We all know that living a stressful lifestyle can take its toll, making us age faster and making us more susceptible to the cold going around the office.

11 Nov 2010

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has received regulatory clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMX-30063, a synthetic defensin-mimetic antibiotic.

11 Nov 2010

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

10 Nov 2010

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

Generex Biotechnology Corporationannounced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. has been awarded two Therapeutic Discovery Project grants, totaling $488,958.50, by the United States Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of 2010.

10 Nov 2010

Amarin reports $31.4 million cash balance for third quarter 2010

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported its financial and operational results for the three-month period ended September 30, 2010.

10 Nov 2010

DATATRAK third quarter revenue increases 17% to $1,818,000

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the third quarter of 2010: $1.8 million revenue, $11.4 million backlog, and continued profitability, resulting in a cash increase over second quarter 2010.

10 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Repros third quarter net loss decreases to $1.2 million

Repros Therapeutics Inc. today announced financial results for the third quarter ended September 30, 2010 and provided an update on corporate actions.

10 Nov 2010

Fibroblast growth factor-2 stimulates periodontal regeneration: Study

It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.

10 Nov 2010

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Idera Pharmaceuticals, Inc. today announced two presentations of preclinical data from its autoimmune and inflammatory disease program at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Atlanta, Georgia. One presentation is entitled "IMO-3100, a Toll-like Receptor (TLR) Antagonist, Suppresses TLR7- and TLR9-mediated Immune Responses in Non-human Primates" (#856).

10 Nov 2010

Regional workshop to discuss diarrheal disease solutions for Asia

Each year, diarrheal disease claims the lives of 1.3 million children under five worldwide and hospitalizes millions more. The vast majority of these deaths occur in developing countries of Asia and Africa, but fortunately, interventions exist that can greatly reduce deaths and save lives. To bring attention to the solutions available today for defeating diarrhea, the Vietnam Ministry of Health, the National Pediatric Hospital of Vietnam, and PATH are hosting a two-day regional workshop where they will present the evidence and lessons learned from initiatives currently underway.

10 Nov 2010

NEWMEDS launches largest database to advance drug development for depressio, schizophrenia

In a remarkable and unprecedented collaboration NEWMEDS (Novel Methods leading to NeW MEdications in Depression and Schizophrenia) have pooled resources to bring together data of 23,401 anonymized patients from 67 trials on 11 compounds in over 25 countries to form the single largest database of clinical trial data ever amassed in psychiatric research.

10 Nov 2010

Neogenix awarded $488,958.50 grant under QTDP program

Neogenix Oncology, Inc. announced today that the company has been awarded two grants totaling $488,958.50, under the Qualifying Therapeutic Discovery Project Program. The two successful applications were for the company's h16C3 therapeutic antibody development program and the diagnostic biomarker development program for both their h16C3 and NPC-1C antibodies.

10 Nov 2010

L. reuteri Prodentis effective for treating chronic periodontitis

The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis.

10 Nov 2010

Only one-third of young women complete HPV regimen

Despite strong evidence of its effectiveness, few of the young women who are eligible for the human papillomavirus (HPV) vaccine take it, according to research presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10.

10 Nov 2010

Clinical Trial News and Research

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

Aradigm reports $1.3M net income for third quarter 2010 vs. $3.0M net loss for third quarter 2009

Labopharm third quarter total revenue increases to $9.6 million

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Exhausted neurons die prematurely and trigger disease symptoms

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

Amarin reports $31.4 million cash balance for third quarter 2010

DATATRAK third quarter revenue increases 17% to $1,818,000

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Repros third quarter net loss decreases to $1.2 million

Fibroblast growth factor-2 stimulates periodontal regeneration: Study

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Regional workshop to discuss diarrheal disease solutions for Asia

NEWMEDS launches largest database to advance drug development for depressio, schizophrenia

Neogenix awarded $488,958.50 grant under QTDP program

L. reuteri Prodentis effective for treating chronic periodontitis

Only one-third of young women complete HPV regimen

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery